Guangzhou Pluslife Biotech Co., Ltd.
PrivateLast Round
Series B
Nov 19, 2025
Total Funding Raised
$37.56M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Guangzhou Pluslife Biotech Co., Ltd. operates in Healthcare & Life Sciences and is based in Guangzhou. Its latest recorded funding round was a Series B round in November 2025.
Guangzhou Pluslife Biotech Co., Ltd. is a biotechnology company that specializes in the research, development, and manufacturing of advanced molecular point-of-care testing diagnostic systems.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Guangzhou Pluslife Biotech Co., Ltd. Comparables
Compare Guangzhou Pluslife Biotech Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ustar Biotechnologies (Hangzhou) Ltd. | 88% | |
| Coyote Bioscience Co., Ltd. | 82% | |
| Aptitude Medical | 80% |
For institutional investors. Book with your work email.
Guangzhou Pluslife Biotech Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 19, 2025 | ||||
| Grant | Oct 1, 2025 | ||||
| Grant | Nov 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Guangzhou Pluslife Biotech Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gates Foundation | Grant |
| Puhua Capital | Series B |
| Qiming Venture Partners | Series B |
| Guangzhou Guoju Venture Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Grew 22% QoQ, from 37 to 45 employees.
- Mar 25, 2026
Grew 19% QoQ, from 31 to 37 employees.
For institutional investors. Book with your work email.
Guangzhou Pluslife Biotech Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Guangzhou Pluslife Biotech Co., Ltd.'s valuation, stock price, and market status.
Is Guangzhou Pluslife Biotech Co., Ltd. a public or private company?
Guangzhou Pluslife Biotech Co., Ltd. is a private company.
What is the current stock price of Guangzhou Pluslife Biotech Co., Ltd.?
Guangzhou Pluslife Biotech Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Guangzhou Pluslife Biotech Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Guangzhou Pluslife Biotech Co., Ltd. worth (valuation)?
Valuation information for Guangzhou Pluslife Biotech Co., Ltd. is not publicly available.
Can I buy Guangzhou Pluslife Biotech Co., Ltd. stock?
Guangzhou Pluslife Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Guangzhou Pluslife Biotech Co., Ltd.'s last funding round?
Guangzhou Pluslife Biotech Co., Ltd.'s most recent funding round was Series B on November 19, 2025.
Who are the main investors in Guangzhou Pluslife Biotech Co., Ltd.?
Key investors in Guangzhou Pluslife Biotech Co., Ltd. include Gates Foundation, Guangzhou Guoju Venture Capital.
Will Guangzhou Pluslife Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Guangzhou Pluslife Biotech Co., Ltd..
How can I track Guangzhou Pluslife Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Guangzhou Pluslife Biotech Co., Ltd.'s shares on secondary markets.